JP2019520369A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019520369A5 JP2019520369A5 JP2018568727A JP2018568727A JP2019520369A5 JP 2019520369 A5 JP2019520369 A5 JP 2019520369A5 JP 2018568727 A JP2018568727 A JP 2018568727A JP 2018568727 A JP2018568727 A JP 2018568727A JP 2019520369 A5 JP2019520369 A5 JP 2019520369A5
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- salt
- formula
- alkyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16178030 | 2016-07-05 | ||
| EP16178030.9 | 2016-07-05 | ||
| PCT/IB2017/053971 WO2018007919A1 (en) | 2016-07-05 | 2017-06-30 | New process for early sacubitril intermediates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019520369A JP2019520369A (ja) | 2019-07-18 |
| JP2019520369A5 true JP2019520369A5 (enExample) | 2020-08-13 |
| JP6944473B2 JP6944473B2 (ja) | 2021-10-06 |
Family
ID=56363778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568727A Expired - Fee Related JP6944473B2 (ja) | 2016-07-05 | 2017-06-30 | 初期サクビトリル中間体のための新規な方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20190256454A1 (enExample) |
| EP (1) | EP3481799A1 (enExample) |
| JP (1) | JP6944473B2 (enExample) |
| CN (1) | CN109415308B (enExample) |
| WO (1) | WO2018007919A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201903302UA (en) | 2016-10-14 | 2019-05-30 | Xencor Inc | Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments |
| US11084863B2 (en) | 2017-06-30 | 2021-08-10 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains |
| CN112867734A (zh) | 2018-04-18 | 2021-05-28 | Xencor股份有限公司 | 包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途 |
| JP2021520829A (ja) | 2018-04-18 | 2021-08-26 | ゼンコア インコーポレイテッド | ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質 |
| IL278090B2 (en) | 2018-04-18 | 2024-07-01 | Xencor Inc | Il-15/il-15rα heterodimeric fc fusion proteins and uses thereof |
| CA3116188A1 (en) | 2018-10-12 | 2020-04-16 | Xencor, Inc. | Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof |
| EP3897853A1 (en) | 2018-12-20 | 2021-10-27 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| CN111205204A (zh) * | 2020-01-16 | 2020-05-29 | 南京红杉生物科技有限公司 | 沙库必曲中间体及其合成方法、应用 |
| CN115745841B (zh) * | 2021-09-03 | 2024-04-16 | 凯特立斯（深圳）科技有限公司 | 一种沙库必曲中间体的制备方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2516098A (en) * | 1949-03-26 | 1950-07-25 | Parke Davis & Co | Biphenyl compounds |
| US2543267A (en) * | 1950-01-04 | 1951-02-27 | Parke Davis & Co | Hydroxyethyl-acylamidobiphenylyl ketones |
| CA1182125A (en) * | 1978-11-25 | 1985-02-05 | Hamao Umezawa | Process for producing threo-3-amino-2- hydroxybutanoyl-aminoacetic acids, as well as novel intermediates therefor and process for producing them |
| JPS5690050A (en) * | 1979-11-20 | 1981-07-21 | Microbial Chem Res Found | Novel threo-3-amino-2-hydroxybutanoylaminoacetic acid |
| US5217996A (en) | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
| US7329775B2 (en) * | 2003-10-30 | 2008-02-12 | Northwestern University | Compounds and related methods for mutant p53 reactivation |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| WO2007083774A1 (ja) | 2006-01-17 | 2007-07-26 | Sumitomo Chemical Company, Limited | ビフェニルメチルヒダントイン化合物、その製造方法、及びそれを用いるビフェニルアラニン化合物の製造方法 |
| EP1980622B1 (en) | 2006-01-17 | 2010-08-18 | Sumitomo Chemical Company, Limited | Method for production of an optically active biphenylalanine compound or salt or ester thereof |
| EP1903027A1 (en) | 2006-09-13 | 2008-03-26 | Novartis AG | Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors |
| BRPI0806700A8 (pt) | 2007-01-12 | 2019-01-22 | Novartis Ag | processo |
| WO2008120567A1 (ja) | 2007-03-20 | 2008-10-09 | Sumitomo Chemical Company, Limited | Ｌ－ビフェニルアラニン化合物の塩の回収方法、およびそれを用いたビフェニルアラニンエステル化合物の回収方法 |
| KR100817977B1 (ko) | 2007-05-03 | 2008-03-31 | 엘에스전선 주식회사 | 2차 전지용 음극재 및 이를 이용한 2차 전지 |
| AR070176A1 (es) | 2008-01-17 | 2010-03-17 | Novartis Ag | Procesos de sintesis de inhibidores de nep, compuestos intermediarios y uso de los mismos en la sintesis |
| CN101774941A (zh) | 2009-01-13 | 2010-07-14 | 浙江九洲药业股份有限公司 | 2-酰基氨基-3-联苯基丙酸的制备及拆分方法 |
| KR101821090B1 (ko) | 2009-09-23 | 2018-01-22 | 제지앙 지우조우 파마슈티칼 컴퍼니 리미티드 | Ｎ-아실비페닐 알라닌의 제조 방법 |
| US9067883B2 (en) | 2010-01-22 | 2015-06-30 | Novartis Ag | Intermediates of neutral endopeptidase inhibitors and preparation method thereof |
| CN102260177A (zh) | 2010-05-25 | 2011-11-30 | 中国医学科学院药物研究所 | 丙二醇类衍生物、其制备方法和其药物组合物与用途 |
| EP2609071B1 (en) | 2010-08-23 | 2016-09-21 | Novartis AG | New process for the preparation of intermediates useful for the manufacture of nep inhibitors |
| AU2011295170B2 (en) | 2010-08-23 | 2014-12-18 | Novartis Ag | Process for the preparation of intermediates for the manufacture of NEP inhibitors |
| CN106977418A (zh) | 2011-08-19 | 2017-07-25 | Dpx精细化学奥地利两合公司 | R‑联苯丙氨醇的合成 |
| AR092278A1 (es) | 2012-08-31 | 2015-04-08 | Novartis Ag | Proceso de obtencion de derivados n-acilicos de bifenil-alanina e intermediarios relacionados |
| CN105473546A (zh) | 2013-08-21 | 2016-04-06 | DPx控股有限公司 | 通过新颖的中间体合成联苯丙氨醇 |
| CN103483201A (zh) | 2013-09-12 | 2014-01-01 | 江苏弘和药物研发有限公司 | 一种(r)-2-甲基-4-硝基-1-丁醇的合成方法 |
| CN104557600B (zh) | 2015-01-26 | 2016-05-04 | 苏州明锐医药科技有限公司 | 沙库比曲的制备方法 |
| CN104725256B (zh) | 2015-02-11 | 2018-03-16 | 威海迪素制药有限公司 | 一种联苯丙氨酸衍生物的制备方法 |
| CN104725279B (zh) | 2015-02-12 | 2018-03-02 | 威海迪素制药有限公司 | 一种N‑Boc‑联苯丙氨酸衍生物的制备方法 |
| CN105017082B (zh) | 2015-07-31 | 2017-09-19 | 上海皓元医药股份有限公司 | 一种心衰药Entresto 关键中间体(R)‑叔丁基 (1‑([1,1`‑联苯]‑4‑基)‑3‑羟基丙烷‑2‑基)氨基甲酸酯的制备方法 |
| CN105061263B (zh) | 2015-08-11 | 2017-03-15 | 苏州楚凯药业有限公司 | 一种nep抑制剂中间体的制备方法 |
| CN105085322B (zh) | 2015-08-15 | 2017-10-03 | 浙江永宁药业股份有限公司 | Ahu‑377中间体的制备方法及其中间体和中间体的制备方法 |
| CN105168205A (zh) * | 2015-08-18 | 2015-12-23 | 泰力特医药（湖北）有限公司 | 一种血管紧张素ii受体和脑啡肽酶受体双重抑制剂lcz696的制备方法 |
| CN105330569A (zh) | 2015-09-11 | 2016-02-17 | 天台宜生生化科技有限公司 | 一种(r)-2-(n-叔丁氧羰基氨基)联苯丙醇的制备方法 |
| CN105152980B (zh) | 2015-09-11 | 2017-03-29 | 浙江永宁药业股份有限公司 | N‑叔丁氧羰基‑（4s）‑（对苯基苯基甲基）‑4‑氨基‑（2r）‑甲基丁酸的手性制备方法 |
| CN105198775B (zh) | 2015-10-10 | 2017-11-14 | 凯瑞斯德生化(苏州)有限公司 | 一种手性N‑Boc联苯丙氨醇的制备方法 |
| CN105237560B (zh) | 2015-10-15 | 2018-07-06 | 上海博氏医药科技有限公司 | 一种lzc696中间体及其合成方法 |
| CN105481622A (zh) | 2015-12-14 | 2016-04-13 | 武汉凯特立斯科技有限公司 | 一种α-氧代-α,β-不饱和羧酸的不对称氢化方法 |
| CN105566194A (zh) | 2016-02-01 | 2016-05-11 | 张伯引 | 一种Sacubitril中间体的制备方法 |
| CN105601524B (zh) | 2016-03-17 | 2017-09-29 | 海门慧聚药业有限公司 | Lcz696关键中间体的制备 |
| WO2017203474A1 (en) * | 2016-05-27 | 2017-11-30 | Dr. Reddy's Laboratories Limited | Process for preparation of sacubutril intermediate |
-
2017
- 2017-06-30 JP JP2018568727A patent/JP6944473B2/ja not_active Expired - Fee Related
- 2017-06-30 EP EP17743393.5A patent/EP3481799A1/en not_active Withdrawn
- 2017-06-30 CN CN201780041934.1A patent/CN109415308B/zh not_active Expired - Fee Related
- 2017-06-30 US US16/314,933 patent/US20190256454A1/en not_active Abandoned
- 2017-06-30 WO PCT/IB2017/053971 patent/WO2018007919A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019520369A5 (enExample) | ||
| KR102885432B1 (ko) | CCR8 억제제로 Tregs를 표적화하는 방법 및 조성물 | |
| CA2686387C (en) | 1, 3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase | |
| JP2016536316A5 (enExample) | ||
| RS55876B1 (sr) | Ciklične n,n`-diariltiouree i n,n`-diariluree kao antagonisti receptora androgena, antikancerogeno sredstvo, postupak za njegovu proizvodnju i primenu | |
| JP2009534358A5 (enExample) | ||
| US20210002221A1 (en) | Catalysts and methods for enantioselecive conjugate addition of amines to unsaturated electrophiles | |
| WO2010076033A1 (en) | Toluidine sulfonamides and their use | |
| JPH07196511A (ja) | キノキサリンおよびヌクレオシドを含有する複合製剤 | |
| JPWO2006028161A1 (ja) | セロトニン５−ｈｔ３受容体作動薬 | |
| S. Amim et al. | Synthesis, Antitubercular and Anticancer Activities of p-nitrophenylethylenediamine-derived Schiff Bases | |
| Faldu et al. | Characterization and antitubercular activity of synthesized pyrimidine derivatives via chalcones | |
| CA3001547C (en) | Method for purifying benzopyran derivative, crystal form thereof, and method for preparing crystal form | |
| JP2016017040A (ja) | ヒドロキサム酸誘導体及びｈｄａｃ８阻害剤 | |
| JPS606658A (ja) | 三置換オキサゾリジノン化合物 | |
| RU2653511C2 (ru) | 4-метил-n-2,4-диметилфенил-6-(3-фторфенил)-2-тиоксо-1,2,3,6-тетрагидропиримидин-5-карбоксамид, проявляющий анальгетическое действие | |
| ES2531458T3 (es) | Proceso catalítico para hidrogenación asimétrica | |
| KR20160117843A (ko) | 결정형 및 이의 제조방법 | |
| RU2571102C1 (ru) | Замещенные хлориды 2-[(1z)-1-(3,5-диарил-1,3,4-тиадиазол-2(3h)-илиден)метил]-3,5-диарил-1,3,4-тиадиазол-3-ия и способ их получения | |
| WO2012151114A1 (en) | Diazeniumdiolate cyclohexyl derivatives | |
| WO2007144128A1 (en) | Pyrrolidine compounds as renin inhibitors | |
| JP7277927B2 (ja) | カチオン性親油基を含むバルビツール酸誘導体 | |
| RU2021135671A (ru) | Производное индазола, способ его получения и его фармацевтическое применение | |
| Pavlov | Synthesis of 2-cyano-1-(4-nitrophenyl) pyrrole and its 5-bromo-and 4, 5-dibromo derivatives | |
| WO2015044928A1 (en) | Substituted indoles and their use as non-nucleoside reverse transcriptase inhibitors |